SPOT-MAS™ Cancer Screening
SPOT-MAS™ Cancer Screening is a simple blood test that screens for up to 10 common and aggressive cancers. Powered by DNA sequencing and AI, this multi-cancer early detection test helps identify cancer signals at their earliest stages.
SPOT-MAS™ cancer screening test is based on detection and analysis of the DNA fragments (circulating tumor DNA or ctDNA) released by tumor cells into the bloodstream.
This non-invasive blood test allows early detection, enabling timely intervention and treatment, improving outcomes.
10 Common Cancers Covered By SPOT-MAS™ Cancer Screening
SPOT-MAS™ Cancer Screening At A Glance
Proven Accuracy
Reliable detection with 78.1% sensitivity, 99.8% specificity, and 84% tissue origin accuracy.
10 Cancers Screened
Detects early signals of 10 common cancers in Singapore, when treatment is most effective.
Non-Invasive
No surgery, no biopsy, no downtime. A simple blood test, no fasting required.
Recommended Profiles
For adults above 40 or below 40 with heavy smoking or drinking, family history of cancer or liver diseases such as Hepatitis B or C.
Comprehensive Insights
Early detection of multiple cancers in a single test before symptoms appear, compared to conventional one-cancer screenings.
Personalised Follow-up
Cancer screening test results are reviewed by experienced medical professionals to provide tailored recommendations.
Why Cancer Screen Early?
Early cancer screening can detect cancers before symptoms appear, giving you the best chance for timely treatment, lower costs, and better recovery.
>90% survival if cancers detected early*
* Applies to breast and colorectal cancers when found early
Higher Survival with Early Diagnosis
Lower Medical Expenses
The White-Glove Experience
Dedicated Concierge Support
Effortlessly access information and schedule your teleconsultation—all through the convenience of WhatsApp.
Doctor Consult
Understand the test pre- screening and discuss your results with our doctor at your convenience via teleconsultation.
Homebased Service
Complete your screening in comfort and privacy of your home, without any disruption to your schedule.
SPOT-MAS™ Cancer Screening
$788
(incl. gst)
10 Cancer Types
Breast, Lung, Colorectum, Stomach, Head & Neck, Endometrium, Pancreas, Esophagus, Ovary and Liver–Biliary Tract.
*Suitable for male and female
Register Your Interest
Our Customer Care team will be in touch within 3 working days to schedule a doctor consultation. You can learn more about the test and decide if it is right for you.
Frequently Asked Questions
SPOT-MAS Cancer Screening
SPOT-MAS is a non-invasive, multi-cancer early detection test performed through a simple blood draw. It uses next-generation sequencing and AI to analyse multiple biological signals in circulating tumor DNA (ctDNA) — including methylation patterns, fragment size, and genomic features — that may indicate the presence of cancer.
No. SPOT-MAS is designed to complement, not replace, standard screening methods such as mammograms, colonoscopies, or Pap smears. These tests remain important even if your SPOT-MAS result is negative.
Many cancers have no symptoms or screening options in their early stages. Detecting cancer early can make treatment more effective, less invasive, and improve survival outcomes.
It is typically recommended to have SPOT-MAS screenings annually. Regular annual screenings play a vital role in detecting cancer at its earliest stages, when treatment is often most effective. These screenings also help monitor changes in your health over time. Our Minmed doctor will determine the most suitable screening frequency based on your individual risk factors and medical history.
Results are typically available within 21 working days. We will contact you once the analysis is complete, and our Minmed doctor will review your report with you.
SPOT-MAS is recommended in conjunction with existing health screening for:
Individuals aged 40 and above with no personal history of cancer
Younger adults with higher risk factors, such as:
· Family history of cancer
· Certain genetic predispositions
· Lifestyle risks (e.g., smoking, heavy alcohol use)
· Chronic hepatitis B or C
· Individuals who have been diagnosed with cancer within 5 years
· Individuals who have highly suspected signs of cancer
>> Have breast/thyroid lesions with BI-RADS/TI-RADS ≥ 5
>> Have lung/liver lesions with LUNG-RADS/LI-RADS ≥ 4
>> Have polyps ≥ 1cm or warts/ulcers suspected of malignancy through digestive endoscopy
· Individuals who are pregnant
· Individuals with a history of bone marrow transplant or whole blood transfusion (within 3 months)
SPOT-MAS has been clinically validated in large studies involving thousands of participants.
It achieves:
Sensitivity: ~70–78% (ability to detect cancer when it is present)
Specificity: ~99% (very low false positives)
Tumor origin prediction: ~84% accuracy
The SPOT-MAS™ cancer screening test is a multi-cancer early detection test that works by analysing circulating tumour DNA (ctDNA) — tiny DNA fragments released into the bloodstream by cancer cells.
Traditional cancer marker tests measure protein levels linked to certain cancers. However, these tests generally have lower sensitivity and specificity, which may limit accuracy.
In contrast, SPOT-MAS™ uses DNA sequencing and AI to deliver more accurate and reliable detection, making it a powerful tool for identifying cancer signals early.
A “Detected” result means that cancer signals were found in your blood. This does not confirm cancer. Consult our Minmed doctor immediately for recommended further targeted tests for diagnosis.
An “Intermediate” result means the signal is inconclusive. Please consult our Minmed doctor for a repeat test within 6 months and to continue with your routine health screenings.
SPOT-MAS cancer screen detects early signals of 10 common cancers frequently found in Singapore including Breast, Lung, Colorectum, Stomach, Head & Neck, Endometrium, Pancreas, Esophagus, Ovary and Liver–Biliary Tract.
SPOT-MAS cancer screening test report ready within 21 working days, with a detailed post-review consultation with our doctors.